GlassScriptPhysician profile
Karim Anwar
NPI 1053350140
$14,784.18
in general payments reported to CMS, 2019-2025
66 companies · $2,422 in 2025
The $2,422 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,495 · 2020: $99.10 · 2021: $11.92 · 2022: $4,868 · 2023: $808 · 2024: $4,080 · 2025: $2,422.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,536 · Consulting Fee: $1,621 · Education: $153.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,536.01 |
| Consulting Fee | $1,621.00 |
| Education | $152.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,703.10 | 2019-2025 | Imfinzi, Lynparza, Tagrisso |
| Genzyme Corporation | $1,882.33 | 2022-2025 | |
| Exelixis INC. | $1,791.29 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $1,241.92 | 2022-2024 | |
| Pfizer INC. | $911.22 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $827.34 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $356.38 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Abbvie INC. | $342.53 | 2022-2025 | |
| Janssen Biotech, INC. | $334.92 | 2019-2025 | Tecvayli, Darzalex, Erleada |
| Daiichi Sankyo INC. | $296.91 | 2022-2025 | Datroway, Enhertu, Injectafer |
| Astellas Pharma US INC | $177.70 | 2019-2025 | Xospata, Vyloy, Xtandi |
| Glaxosmithkline, LLC. | $172.38 | 2020-2025 | Ojjaara |
| Ipsen Biopharmaceuticals, INC | $141.36 | 2022-2025 | Onivyde |
| Array Biopharma INC | $128.28 | 2022-2025 | Braftovi, Mektovi, Lorbrena |
| Gilead Sciences, INC. | $128.12 | 2019-2025 | Trodelvy |
Show all 66 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karim Anwar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.